Company Focus
Chugai
Latest Chugai News
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders.
Latest News & Features of interest to Chugai
Biotechnology
The US Food and Drug Administration (FDA) has accepted the New Drug Application and granted Priority Review to inavolisib, an investigational, oral therapy, in combination with palbociclib (Ibrance) and fulvestrant, under development by Swiss pharma giant Roche. 29 May 2024
Pharmaceutical
Ikena Oncology has announced the discontinuation of its IK-930 program, as well as plans to slash its workforce by about 50%. 29 May 2024
Biotechnology
Less than two years after it was launched, San Francisco-based start-up Cartography Biosciences has announced a deal with nearby biotech major, Gilead Sciences. 29 May 2024
Pharmaceutical
Russia has suspended state purchases of a number of original anti-cancer drugs due to problems associated with sanctions and the ever-growing isolation of the country in the international arena, The Pharma Letter’s local correspondent reports. 29 May 2024
Pharmaceutical
Cambridge, USA-based Agios Pharmaceuticals closed up more than 23% at $38.81 yesterday, after it revealed it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to Royalty Pharma. 29 May 2024
Pharmaceutical
IDEAYA Biosciences, a precision oncology company, has recruited Daniel Simon to the role of chief business officer. 28 May 2024
Biotechnology
China’s MediLink Therapeutics has forged a new agreement with German advanced therapy company BioNTech. 28 May 2024
Biotechnology
Privately-held Swiss drug firm Ewopharma it has entered into a strategic commercial collaboration with China’s CStone Pharmaceuticals to gain rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). 28 May 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) alongside bortezomib, lenalidomide and dexamethasone (VRd) for transplant-ineligible newly diagnosed multiple myeloma (NDMM). 28 May 2024
Biotechnology
AstraZeneca has reported top-line overall survival results from the Phase III TROPION-Lung01 study. 28 May 2024
Latest In Brief for Chugai
Latest Relevant Ones To Watch News
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
13 November 2024
30 October 2024
28 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze